Urokinase-type plasminogen activator receptor (uPAR) as a promising new imaging target: Potential clinical applications

Clinical Physiology and Functional Imaging

Volumn 33, Issue 5, 2013, Pages 329-337

  Persson, Morten ^a,b,c   Kjaer, Andreas ^a,b,c  

^a Rigshospitalet   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c The Danish Chinese Center for Proteases and Cancer   (Denmark)

Author keywords

Cancer; Human; Mouse; MRI; Oncology; Optical Imaging; Pet; Proteolysis; SPECT; Translational; uPAR uPA

Indexed keywords

GLYCOSYLPHOSPHATIDYLINOSITOL; NOSCAPINE; UROKINASE RECEPTOR;

BINDING AFFINITY; BREAST CANCER; CELL MEMBRANE; CELL SURFACE; CONFOCAL LASER MICROSCOPY; FLUORESCENCE IMAGING; GLIOBLASTOMA; HUMAN; IMAGING; METASTASIS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PLASMINOGEN ACTIVATION; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SPECIES DIFFERENCE; TREATMENT PLANNING; TUMOR INVASION;

CANCER; HUMAN; MOUSE; MRI; ONCOLOGY; OPTICAL IMAGING; PET; PROTEOLYSIS; SPECT; TRANSLATIONAL; UPAR/UPA;

ANIMALS; HUMANS; LIGANDS; MOLECULAR IMAGING; MOLECULAR PROBES; NEOPLASMS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RECEPTORS, UROKINASE PLASMINOGEN ACTIVATOR; TUMOR MARKERS, BIOLOGICAL;

EID: 84880697946     PISSN: 14750961     EISSN: 1475097X     Source Type: Journal    
DOI: 10.1111/cpf.12037     Document Type: Review

References (54)

1. Abdalla MO, Karna P, Sajja HK, Mao H, Yates C, Turner T, Aneja R. Enhanced noscapine delivery using uPAR-targeted optical-MR imaging trackable nanoparticles for prostate cancer therapy. J Control Release (2011); 149: 314-322. doi:10.1016/j.jconrel.2010.10.030.
2. Alpízar-Alpízar W, Christensen IJ, Santoni-Rugiu E, Skarstein A, Ovrebo K, Illemann M, Laerum OD. Urokinase plasminogen activator receptor on invasive cancer cells: a prognostic factor in distal gastric adenocarcinoma. Int J Cancer (2012); 131: E329-E336. doi:10.1002/ijc.26417.
3. Anderson CJ, Wadas TJ, Wong EH, Weisman GR. Cross-bridged macrocyclic chelators for stable complexation of copper radionuclides for PET imaging. Q J Nucl Med Mol Imaging (2008); 52: 185-192.
4. Armstrong AF, Lemon JA, Czorny SK, Singh G, Valliant JF. Evaluation of single amino acid chelate derivatives and regioselective radiolabelling of a cyclic peptide for the urokinase plasminogen activator receptor. Nucl Med Biol (2009); 36: 11-11. doi:10.1016/j.nucmedbio.2009.07.001.
5. Bass LA, Wang M, Welch MJ, Anderson CJ. In vivo transchelation of copper-64 from TETA-octreotide to superoxide dismutase in rat liver. Bioconjug Chem (2000); 11: 527-532.
6. Blasi F, Sidenius N. The urokinase receptor: focused cell surface proteolysis, cell adhesion and signaling. FEBS Lett (2010); 584: 1923-1930. doi:10.1016/j.febslet.2009.12.039.
7. de Bock CE, Wang Y. Clinical significance of urokinase-type plasminogen activator receptor (uPAR) expression in cancer. Med Res Rev (2004); 24: 13-39. doi:10.1002/med.10054.
8. Boswell CA, Sun X, Niu W, Weisman GR, Wong EH, Rheingold AL, Anderson CJ. Comparative in vivo stability of copper-64-labeled cross-bridged and conventional tetraazamacrocyclic complexes. J Med Chem (2004); 47: 1465-1474. doi:10.1021/jm030383 m.
9. Casslen B, Gustavsson B, Astedt B. Cell membrane receptors for urokinase plasminogen activator are increased in malignant ovarian tumours. Eur J Cancer (1991); 27: 1445-1448.
10. Dano K, Behrendt N, Hoyer-Hansen G, Johnsen M, Lund LR, Ploug M, Romer J. Plasminogen activation and cancer. Thromb Haemost (2005); 93: 676-681. doi:10.1267/THRO05040676.
11. Dass K, Ahmad A, Azmi AS, Sarkar SH, Sarkar FH. Evolving role of uPA/uPAR system in human cancers. Cancer Treat Rev (2008); 34: 122-136. doi:10.1016/j.ctrv.2007.10.005.
12. Dublin E, Hanby A, Patel NK, Liebman R, Barnes D. Immunohistochemical expression of uPA, uPAR, and PAI-1 in breast carcinoma. Fibroblastic expression has strong associations with tumor pathology. Am J Pathol (2000); 157: 1219-1227.
13. Duffy MJ, O'Grady P, Devaney D, O'Siorain L, Fennelly JJ, Lijnen HJ. Urokinase-plasminogen activator, a marker for aggressive breast carcinomas. Preliminary report. Cancer (1988); 62: 531-533. doi:10.1002/1097-0142(19880801)62:3%3c531:AID-CNCR2820620315%3e3.0.CO;2-B.
14. Dullin C, Zientkowska M, Napp J, Missbach-Guentner J, Krell HW, Müller F, Grabbe E, Tietze LF, Alves F. Semiautomatic landmark-based two-dimensional-three-dimensional image fusion in living mice: correlation of near-infrared fluorescence imaging of Cy5. 5-labeled antibodies with flat-panel volume computed tomography. Mol Imaging (2009); 8: 2-14.
15. Foekens JA, Peters HA, Look MP, Portengen H, Schmitt M, Kramer MD, Brunner N, Janicke F, Meijer-van Gelder ME, Henzen-Logmans SC, van Putten WL, Klijn JG. The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients. Cancer Res (2000); 60: 636-643.
16. Ganesh S, Sier CF, Heerding MM, Griffioen G, Lamers CB, Verspaget HW. Urokinase receptor and colorectal cancer survival. Lancet (1994); 344: 401-402.
17. Hanahan D, Weinberg RA. Hallmarks of Cancer: The Next Generation. Cell (2011); 144: 29-29. doi:10.1016/j.cell.2011.02.013.
18. Hildenbrand RR, Leitz MM, Magdolen VV, Luther T, Albrecht S, Graeff H, Stutte HJ, Bleyl U, Schmitt M. Validation of immunolocalization of the urokinase receptor expression in ductal carcinoma in situ of the breast: comparison with detection by non-isotopic in-situ hybridization. Histopathology (2000); 36: 499-504. doi:10.1046/j.1365-2559.2000.00899.x.
19. Huai Q, Mazar AP, Kuo A, Parry GC, Shaw DE, Callahan J, Li Y, Yuan C, Bian C, Chen L, Furie B, Furie BC, Cines DB, Huang M. Structure of human urokinase plasminogen activator in complex with its receptor. Science (2006); 311: 656-659. doi:10.1126/science.1121143.
20. Jacobsen B, Ploug M. The urokinase receptor and its structural homologue C4.4A in human cancer: expression, prognosis and pharmacological inhibition. Curr Med Chem (2008); 15: 2559-2573.
21. James ML, Gambhir SS. A molecular imaging primer: modalities, imaging agents, and applications. Physiol Rev (2012); 92: 897-965. doi:10.1152/physrev.00049.2010.
22. Keereweer S, Kerrebijn JDF, Driel PBAA, Xie B, Kaijzel EL, Snoeks TJ, Que I, Hutteman M, van der Vorst JR, Mieog JS, Vahrmeijer AL, van de Velde CJ, Baatenburg de Jong RJ, Lowik CW. Optical image-guided surgery-where do we stand? Mol Imaging Biol (2011); 13: 199-207. doi:10.1007/s11307-010-0373-2.
23. Kriegbaum MC, Persson M, Haldager L, Alpizar-Alpizar W, Jacobsen B, Gardsvoll H, Kjaer A, Ploug M. Rational targeting of the urokinase receptor (uPAR): development of antagonists and non-invasive imaging probes. Curr Drug Targets (2011); 12: 1711-1728.
24. Li ZB, Niu G, Wang H, He L, Yang L, Ploug M, Chen X. Imaging of urokinase-type plasminogen activator receptor expression using a 64Cu-labeled linear peptide antagonist by microPET. Clin Cancer Res (2008); 14: 4758-4766. doi:10.1158/1078-0432.CCR-07-4434.
25. Lin L, Gårdsvoll H, Huai Q, Huang M, Ploug M. Structure-based engineering of species selectivity in the interaction between urokinase and its receptor: implication for preclinical cancer therapy. J Biol Chem (2010); 285: 10982-10992. doi:10.1074/jbc.M109.093492.
26. Liu D, Overbey D, Watkinson L, Giblin MF. Synthesis and characterization of an (111)in-labeled peptide for the in vivo localization of human cancers expressing the urokinase-type plasminogen activator receptor (uPAR). Bioconjug Chem (2009); 20: 888-894. doi:10.1021/bc800433y.
27. Liu Y, Zhou S, Tu D, Chen Z, Huang M, Zhu H, Ma E, Chen X. Amine-functionalized lanthanide-doped zirconia nanoparticles: optical spectroscopy, time-resolved fluorescence resonance energy transfer biodetection, and targeted imaging. J Am Chem Soc (2012); 134: 15083-15090. doi:10.1021/ja306066a.
28. Llinas P, Le Du MH, Gårdsvoll H, Dano K, Ploug M, Gilquin B, Stura EA, Menez A. Crystal structure of the human urokinase plasminogen activator receptor bound to an antagonist peptide. EMBO J (2005); 24: 1655-1663. doi:10.1038/sj.emboj.7600635.
29. Lomholt AF, Christensen IJ, Hoyer-Hansen G, Nielsen HJ. Prognostic value of intact and cleaved forms of the urokinase plasminogen activator receptor in a retrospective study of 518 colorectal cancer patients. Acta Oncol (2010); 49: 805-811. doi:10.3109/0284186X.2010.491086.
30. Mieog JSD, Hutteman M, van der Vorst JR, Kuppen PJ, Que I, Dijkstra J, Kaijzel EL, Prins F, Lowik CW, Smit VT, van de Velde CJ, Vahrmeijer AL. Image-guided tumor resection using real-time near-infrared fluorescence in a syngeneic rat model of primary breast cancer. Breast Cancer Res Treat (2011); 128: 679-689. doi:10.1007/s10549-010-1130-6.
31. Miyake H, Hara I, Yamanaka K, Arakawa S, Kamidono S. Elevation of urokinase-type plasminogen activator and its receptor densities as new predictors of disease progression and prognosis in men with prostate cancer. Int J Oncol (1999a); 14: 535-541.
32. Miyake H, Hara I, Yamanaka K, Gohji K, Arakawa S, Kamidono S. Elevation of serum levels of urokinase-type plasminogen activator and its receptor is associated with disease progression and prognosis in patients with prostate cancer. Prostate (1999b); 39: 123-129. doi:10.1002/(SICI)1097-0045(19990501)39:2%3c123:AID-PROS7%3e3.0.CO;2-2.
33. Nicholl SM, Roztocil E, Davies MG. Plasminogen activator system and vascular disease. Curr Vasc Pharmacol (2006); 4: 101-116.
34. Ossowski LL, Clunie GG, Masucci MTM, Blasi FF. In vivo paracrine interaction between urokinase and its receptor: effect on tumor cell invasion. J Cell Biol (1991); 115: 1107-1112. doi:10.2307/1614881.
35. Persson M, Madsen J, Ostergaard S, Jensen MM, Jorgensen JT, Juhl K, Lehmann C, Ploug M, Kjaer A. Quantitative PET of human urokinase-type plasminogen activator receptor with 64Cu-DOTA-AE105: implications for visualizing cancer invasion. J Nucl Med (2012a); 53: 138-145. doi:10.2967/jnumed.110.083386.
36. Persson M, Madsen J, Ostergaard S, Ploug M, Kjaer A. (68)Ga-labeling and in vivo evaluation of a uPAR binding DOTA- and NODAGA-conjugated peptide for PET imaging of invasive cancers. Nucl Med Biol (2012b); 39: 560-569. doi:10.1016/j.nucmedbio.2011.10.011.
37. Pfeifer A, Knigge U, Mortensen J, Oturai P, Berthelsen AK, Loft A, Binderup T, Rasmussen P, Elema D, Klausen TL, Holm S, von Benzon E, Hojgaard L, Kjaer A. Clinical PET of Neuroendocrine Tumors Using 64Cu-DOTATATE: First-in-Humans Study. J Nucl Med (2012); 53: 1207-1215. doi:10.2967/jnumed.111.101469.
38. Ploug M, Behrendt N, Lober D, Dano K. Protein structure and membrane anchorage of the cellular receptor for urokinase-type plasminogen activator. Semin Thromb Hemost (1991a); 17: 183-193. doi:10.1055/s-2007-1002608.
39. Ploug M, Eriksen J, Plesner T, Hansen NE, Dano K. A soluble form of the glycolipid-anchored receptor for urokinase-type plasminogen activator is secreted from peripheral blood leukocytes from patients with paroxysmal nocturnal hemoglobinuria. Eur J Biochem (1992); 208: 397-404.
40. Ploug M, Ostergaard S, Gårdsvoll H, Kovalski K, Holst-Hansen C, Holm A, Ossowski L, Dano K. Peptide-derived antagonists of the urokinase receptor. affinity maturation by combinatorial chemistry, identification of functional epitopes, and inhibitory effect on cancer cell intravasation. Biochemistry (2001); 40: 12157-12168.
41. Pyke C, Graem N, Ralfkiaer E, Ronne E, Hoyer-Hansen G, Brunner N, Dano K. Receptor for urokinase is present in tumor-associated macrophages in ductal breast carcinoma. Cancer Res (1993); 53: 1911-1915.
42. Pyke CC, Ralfkiaer EE, Rønne E, Hoyer-Hansen G, Kirkeby L, Dano K. Immunohistochemical detection of the receptor for urokinase plasminogen activator in human colon cancer. Histopathology (1994); 24: 131-138. doi:10.1111/j.1365-2559.1994.tb01291.x.
43. Rasch MG, Lund IK, Almasi CE, Hoyer-Hansen G. Intact and cleaved uPAR forms: diagnostic and prognostic value in cancer. Front Biosci (2008); 13: 6752-6762.
44. Riggenbach NN, von KAULLA KNK. Urokinase excretion in patients with carcinoma. Cancer (1960); 14: 889-896. doi:10.1002/1097-0142(199007/08)14:4%3c889:AID-CNCR2820140428%3e3.0.CO;2-L.
45. Riisbro R, Christensen IJ, Piironen T, Greenall M, Larsen B, Stephens RW, Han C, Hoyer-Hansen G, Smith K, Brunner N, Harris AL. Prognostic significance of soluble urokinase plasminogen activator receptor in serum and cytosol of tumor tissue from patients with primary breast cancer. Clin Cancer Res (2002); 8: 1132-1141.
46. Stephens RW, Nielsen HJ, Christensen IJ, Thorlacius-Ussing O, Sorensen S, Dano K, Brunner N. Plasma urokinase receptor levels in patients with colorectal cancer: relationship to prognosis. J Natl Cancer Inst (1999); 91: 869-874.
47. Van den Eynden GG, Van Laere SJ, Van der Auwera I, Trinh XB, Van Marck EA, Dirix LY, Vermeulen PB. Two distinct expression patterns of urokinase, urokinase receptor and plasminogen activator inhibitor-1 in colon cancer liver metastases. Int J Cancer (2009); 125: 1494-1496.
48. Vassalli JD, Baccino D, Belin D. A cellular binding site for the Mr 55, 000 form of the human plasminogen activator, urokinase. J Cell Biol (1985); 100: 86-92.
49. Wang M, Lowik DW, Miller AD, Thanou M. Targeting the urokinase plasminogen activator receptor with synthetic self-assembly nanoparticles. Bioconjug Chem (2009); 20: 32-40. doi:10.1021/bc8001908.
50. Weisman GR, Rogers ME, Wong EH, Jasinski JP, Paight ES. Cross-Bridged Cyclam - Protonation and Li+ Complexation in a Diamond-Lattice Cleft. J Am Chem Soc (1990); 112: 8604-8605.
51. de Witte JHJ, Foekens JAJ, Brünner NN, Heuvel JJ, van Tienoven T, Look MP, Klijn JG, Geurts-Moespot A, Grebenchtchikov N, Benraad T, Sweep CG. Prognostic impact of urokinase-type plasminogen activator receptor (uPAR) in cytosols and pellet extracts derived from primary breast tumours. Br J Cancer (2001); 85: 85-92. doi:10.1054/bjoc.2001.1867.
52. Yang L, Mao H, Cao Z, Wang YA, Peng X, Wang X, Sajja HK, Wang L, Duan H, Ni C, Staley CA, Wood WC, Gao X, Nie S. Molecular imaging of pancreatic cancer in an animal model using targeted multifunctional nanoparticles. Gastroenterology (2009a); 13615141525.e2. doi:10.1053/j.gastro.2009.01.006.
53. Yang L, Peng XH, Wang YA, Wang X, Cao Z, Ni C, Karna P, Zhang X, Wood WC, Gao X, Nie S, Mao H. Receptor-targeted nanoparticles for in vivo imaging of breast cancer. Clin Cancer Res (2009b); 15: 4722-4732. doi:10.1158/1078-0432.CCR-08-3289.
54. Yang Y, Adelstein SJ, Kassis AI. General approach to identifying potential targets for cancer imaging by integrated bioinformatics analysis of publicly available genomic profiles. Mol Imaging (2011); 10: 123-134.